Policy Briefs | The Initiative on Enabling Choice and Competition in Health Care

Policy Brief: The Impact of Price Setting at 9 Years on Small Molecule Innovation Under the Inflation Reduction Act | October 2023

by mheinl | Oct 3, 2023

This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...

Policy Brief: The Potentially Larger Than Predicted Impact of the IRA on Small Molecule R&D and Patient Health | August 2023

by mheinl | Aug 25, 2023

This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient health with respect to small molecule drugs. Initial evidence potentially suggests that the cutbacks in R&D have...

Policy Brief: The Value of Multi-Cancer Early Detection Tests and Limits to Estimating Budget Impacts of Legislation Proposed to Enable Medicare Access | June 2023

by sfrazee | Jun 10, 2023

This policy brief reviews the evidence on the health and cost impacts of multi-cancer early detection (MCED) tests, and the implications for proposed legislation to enhance their utilization in Medicare. We find that the evidence base suggests that MCED screening...

Policy Brief: The Role of Medical Innovation in Reducing Health Disparities and the Impact of the Inflation Reduction Act | February 2023

by mheinl | Feb 15, 2023

The Biden administration has made reducing health disparities a major goal of its health care agenda. This paper provides analysis of whether and how biopharmaceutical innovation has historically reduced disparities in health outcomes and how reducing such innovation...

Restrict the Middleman? Quantitative Models of PBM Regulations and their Consequences | February 2023

by mheinl | Feb 15, 2023

This paper provides the first quantitative economic models of pharmacy benefit management (PBM) regulation. Indeed, few economic models of the pharmaceutical industry even acknowledge that drug benefits are managed and that companies specialize in benefit management....

« Older Entries

Policy Brief: The Impact of Price Setting at 9 Years on Small Molecule Innovation Under the Inflation Reduction Act | October 2023

Policy Brief: The Potentially Larger Than Predicted Impact of the IRA on Small Molecule R&D and Patient Health | August 2023

Policy Brief: The Value of Multi-Cancer Early Detection Tests and Limits to Estimating Budget Impacts of Legislation Proposed to Enable Medicare Access | June 2023

Policy Brief: The Role of Medical Innovation in Reducing Health Disparities and the Impact of the Inflation Reduction Act | February 2023

Restrict the Middleman? Quantitative Models of PBM Regulations and their Consequences | February 2023

Recent Posts